Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Issue : The Pharmaceutical Journal, October 2014

Sort by: Newest first Oldest first A-Z Z-A

  • Health Care in Danger Subscription

    3 NOV 2014 12:04

    A new e-learning module, specifically designed to help healthcare personnel understand the effects of violence on healthcare, their own rights and responsibilities and ethical dilemmas they may face in armed conflicts and other emergencies, has been launched by the International Committee of the Red Cross (ICRC). The module is called ‘Health Care in Danger’ and is available for free ...

  • Lacidipine tablets Subscription

    3 NOV 2014 12:00

    Lacidipine tablets 2mg and 4mg are now available from Dr Reddy’s. NHS list price, 28 x 2mg, £2.95 and 28 x 4mg, £3.10.

  • Fork-path-businessman-walking

    Which career pathway: community or hospital pharmacy? Subscription

    31 OCT 2014 13:00 By Gareth Malson

    Are you trying to decide between the hospital and community sectors? Gareth Malson explains what you can expect from both, including responsibilities, salaries and career progression.

  • James Kingland, president of the National Association of Primary Care, argues that questions should be asked about how local enhanced services money is being recirculated

    Questions should be asked about how health commissioners recirculate funding to GPs Subscription

    30 OCT 2014 15:33 By Harriet Adcock

    Income from local enhanced services that were historically delivered by GPs could and should be open to competition, not just recycled to general practice, according to the president of the National Association of Primary Care.

  • Faecal microbiota transplantation (FMT) shows high cure rates for Clostridium difficile infection (CDI),pictured, or infectious diarrhoea

    Research confirms faecal microbiota transplantation is safe and effective Subscription

    24 OCT 2014 13:28 By Coeli Carr

    An age-old treatment has shown remarkable clinical cure rates for Clostridium difficile infection, achieving far better outcomes than antimicrobial therapy.

  • Medicines optimisation dashboard survey Subscription

    21 OCT 2014 14:19

    The Royal Pharmaceutical Society is encouraging members to respond to an NHS England survey on its prototype medicines optimisation dashboard by 31 October 2014. This is a more detailed questionnaire and follows the short survey sent out in September. The survey is available here: http://bit.ly/1COSJnd. 

  • The efficacy and safety of amphotericin plus miltefosine to treat visceral leishmaniasis (VL) patients with HIV will be examined in a Phase III randomized clinical trial in Ethiopia.

    Treatment tested for patients with visceral leishmaniasis and HIV in Africa Subscription

    21 OCT 2014 14:07

    The efficacy and safety of amphotericin plus miltefosine to treat visceral leishmaniasis patients with HIV will be examined in a Phase III randomized clinical trial in Ethiopia.

  • Avoid intercourse when herpes symptoms are present Subscription

    17 OCT 2014 14:23

    The summary of product characteristics for Famvir (famciclovir; Novartis) now states that patients with genital herpes should be advised to avoid intercourse when symptoms are present even if treatment has been initiated. It is also recommended that patients use safer sex practice.

  • Asthma guideline updated Subscription

    17 OCT 2014 14:20

    The Scottish Intercollegiate Guidelines Network has revised the British guideline on the management of asthma. The updated guidance is available from the SIGN website.

  • Drug alert for Amoxil and Augmentin Subscription

    16 OCT 2014 15:54

    The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a class 4 drug alert for specified batches of Amoxil (amoxicillin trihydrate; GlaxoSmithKline) vials for injection 500mg and 1g, and Augmentin (co-amoxiclav; GlaxoSmithKline) intravenous 600mg and 1.2g. This is due to a very low incidence of cracks being found in vials used for packaging of the affected products. The cracks are positioned where the base of the vial meets the side wall and there are concerns that ...

Show  10 per page20 per page50 per page

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.